Selected Publications
View all on PubMed
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial.
Meininger V, Pradat PF, Corse A, Al-Sarraj S, Rix Brooks B, Caress JB, Cudkowicz M, Kolb SJ, Lange D, Leigh PN, Meyer T, Milleri S, Morrison KE, Orrell RW, Peters G, Rothstein JD, Shefner J, Lavrov A, Williams N, Overend P, Price J, Bates S, Bullman J, Krull D, Berges A, Abila B, Meno-Tetang G, Wurthner J.
PLoS One. 2014 May 19;9(5):e97803. doi: 10.1371/journal.pone.0097803. eCollection 2014.
PMID: 24841795
The co-existence of myasthenia gravis in patients with myositis: a case series.
Paik JJ, Corse AM, Mammen AL.
Semin Arthritis Rheum. 2014 Jun;43(6):792-6. doi: 10.1016/j.semarthrit.2013.12.005. Epub 2013 Dec 18.
PMID: 24412588
Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease.
Varsani H, Charman SC, Li CK, Marie SK, Amato AA, Banwell B, Bove KE, Corse AM, Emslie-Smith AM, Jacques TS, Lundberg IE, Minetti C, Nennesmo I, Rushing EJ, Sallum AM, Sewry C, Pilkington CA, Holton JL, Wedderburn LR; the UK Juvenile Dermatomyositis Research Group.
Ann Rheum Dis. 2013 Sep 24. doi: 10.1136/annrheumdis-2013-203396. [Epub ahead of print]
PMID: 24064003
A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis.
Howard JF Jr, Barohn RJ, Cutter GR, Freimer M, Juel VC, Mozaffar T, Mellion ML, Benatar MG, Farrugia ME, Wang JJ, Malhotra SS, Kissel JT; MG Study Group.
Muscle Nerve. 2013 Jul;48(1):76-84. doi: 10.1002/mus.23839. Epub 2013 Apr 30.
PMID: 23512355
Expanding the spectrum of monoclonal light chain deposition disease in muscle.
Ostrow LW, Corse AM, Morrison BM, Huff CA, Carrino JA, Hoke A, Mammen AL.
Muscle Nerve. 2012 May;45(5):755-61. doi: 10.1002/mus.23287.
PMID: 22499107
Patient Ratings & Comments
The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.